Nanozymes have emerged as promising nanomaterials for the treatment of inflammation-related diseases by eliminating excessive reactive oxide species (ROS) and immunoregulation. However, persistent inflammation invariably causes severe alveolar destruction in periodontitis; and the alleviation of inflammation alone by neglecting the impairment of vascular functions could not effectively realize periodontal regeneration. Herein, a multifunctional copper-ruthenium oxide-based yolk-shell nanozyme (Cu 2 O@RuO 2 , CRNC) is designed to promote effective periodontal regeneration. The ruthenium oxide (RuO 2 ) shell serves to alleviate inflammation by eliminating ROS and triggering macrophage polarization, whereas the cuprous oxide (Cu 2 O) core acts as a responsive Cu 2 + nano-reservoir for promoting angiogenesis and osteogenesis. Results demonstrated that CRNC could activate transforming growth factor β/phosphatidylinositol 3-kinase (TGF-β/PI3K) and hypoxia-inducible factors (HIF-1α) signals, aiding angiogenesis in the human umbilical vein endothelial cells and osteogenesis in periodontal ligament stem cells, respectively. The multifunctional CRNC nanozyme successfully decreased periodontal inflammation and ameliorated alveolar regeneration in a periodontitis model. This study provides promising insights into periodontitis treatment by targeting both angiogenesis and osteogenesis.
The emergence of multidrug-resistant pathogens has created a global public health challenge, demanding the development of efficient and safe therapeutic strategies. Herein, we present a novel nanozyme-armed phage system (PA3@RuO 2 ) designed to combat chronic Pseudomonas aeruginosa infections. This system combines the precision of phage therapy with an anti-inflammatory approach. The phage component, PA3, maintains its ability to specifically target and efficiently lyse a broad spectrum of P. aeruginosa strains. Meanwhile, RuO 2 nanozymes with reactive oxygen species-scavenging capabilities localize to infection sites, mitigating inflammation and hypoxia. This dual action enables bacterial clearance and inflammation reduction while ensuring the biocompatibility of PA3@RuO 2 with healthy tissues. In vivo studies further confirm the effectiveness of PA3@RuO 2 in treating chronic P. aeruginosa -induced wound infections and promoting tissue repair. Overall, these findings suggest that PA3@RuO 2 holds promise for developing non-antibiotic antibacterial therapies and advanced disinfection approaches.
危险品化学品经营许可证（带存储）